132 related articles for article (PubMed ID: 3340061)
1. Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin.
Nichols CR; Loehrer PJ; Greist A; Kubilis PS; Hoffman R
Med Pediatr Oncol; 1988; 16(1):12-6. PubMed ID: 3340061
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
3. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
Loehrer PJ; Lauer R; Roth BJ; Williams SD; Kalasinski LA; Einhorn LH
Ann Intern Med; 1988 Oct; 109(7):540-6. PubMed ID: 2844110
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.
Loehrer PJ; Ansari R; Gonin R; Monaco F; Fisher W; Sandler A; Einhorn LH
J Clin Oncol; 1995 Oct; 13(10):2594-9. PubMed ID: 7595712
[TBL] [Abstract][Full Text] [Related]
5. Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
Kredentser DC
Gynecol Oncol; 1991 Nov; 43(2):145-8. PubMed ID: 1743556
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
Faylona EA; Loehrer PJ; Ansari R; Sandler AB; Gonin R; Einhorn LH
J Clin Oncol; 1995 May; 13(5):1209-14. PubMed ID: 7738623
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
8. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
Loehrer PJ; Einhorn LH; Williams SD
J Clin Oncol; 1986 Apr; 4(4):528-36. PubMed ID: 3633952
[TBL] [Abstract][Full Text] [Related]
9. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Haim N; Ben-Shahar M; Epelbaum R
Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
11. Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer.
Einhorn LH; Loehrer PJ
Semin Oncol; 1995 Feb; 22(1 Suppl 2):28-31. PubMed ID: 7846539
[TBL] [Abstract][Full Text] [Related]
12. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.
Motzer RJ; Cooper K; Geller NL; Bajorin DF; Dmitrovsky E; Herr H; Morse M; Fair W; Sogani P; Russo P
Cancer; 1990 Dec; 66(12):2476-81. PubMed ID: 2174300
[TBL] [Abstract][Full Text] [Related]
13. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin.
Haim N; Rosenblatt E; Wollner M; Ben-Shahar M; Epelbaum R; Robinson E
Cancer Chemother Pharmacol; 1992; 30(3):243-4. PubMed ID: 1628376
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors.
Blanke C; Loehrer PJ; Nichols CR; Einhorn LH
Am J Clin Oncol; 1996 Oct; 19(5):487-91. PubMed ID: 8823477
[TBL] [Abstract][Full Text] [Related]
17. VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer.
Evans WK; Stewart DJ; Shepherd FA; Logan D; Goss G; Maroun JA; Wierzbicki R; Warner E; Latreille J; Dahrouge S
Eur J Cancer; 1994; 30A(3):299-303. PubMed ID: 8204348
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non-Hodgkin lymphoma.
Haim N; Drumea K; Epelbaum R; Ben-Shahar M
Am J Clin Oncol; 1999 Feb; 22(1):47-50. PubMed ID: 10025380
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
20. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas.
Goss P; Shepherd F; Scott JG; Baker M; Sutton D; Sutcliffe S
Leuk Lymphoma; 1995 Jun; 18(1-2):123-9. PubMed ID: 8580814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
